← Eichor
Condition: Relapse Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapse Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia
Phase 1 · 4 location(s) · Allterum Therapeutics, Inc · NCT07586618Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Phase 1 · 13 location(s) · Stelexis BioSciences · NCT06533761Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Phase 2 · 1 location(s) · Shenzhen University General Hospital · NCT07563179Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Do
Phase 1 · 5 location(s) · Celyad Oncology SA · NCT04167696Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Phase N/A · 14 location(s) · University Hospital, Clermont-Ferrand · NCT05246345CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Phase 2 · 1 location(s) · Daihong Liu · NCT07321301A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
Phase 1 · 2 location(s) · ImmunityBio, Inc. · NCT07556757A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532203Orphan Indications for CD19 Redirected Autologous T Cells
Phase 2 · 1 location(s) · Stephan Grupp MD PhD · NCT042768708-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Le
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05263284Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT05445011A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase 1/Phase 2 · 11 location(s) · IDP Discovery Pharma S.L. · NCT05908409xDRIVE for Florida-based Cancer Patients
NA · 2 location(s) · First Ascent Biomedical Inc. · NCT07167381A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
EARLY_Phase 1 · 1 location(s) · He Huang · NCT04227015Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 · 11 location(s) · Juventas Cell Therapy Ltd. · NCT04684147A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06879847Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Predict
Phase N/A · 2 location(s) · Peking University People's Hospital · NCT06452732A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1/Phase 2 · 57 location(s) · Syndax Pharmaceuticals · NCT04065399A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Phase 2 · 2 location(s) · ETH Zurich · NCT06138990Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL o
Phase 1/Phase 2 · 24 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT05791409Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06326008A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Phase 1/Phase 2 · 9 location(s) · Juventas Cell Therapy Ltd. · NCT05667506HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignanci
Phase 1/Phase 2 · 36 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05658640BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06660368Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 · 1 location(s) · CytoCares Inc · NCT06037018A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532268Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies W
Phase N/A · 3 location(s) · National Cancer Institute (NCI) · NCT05237986Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Phase 4 · 1 location(s) · Chinese PLA General Hospital · NCT07101588
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.